Hansa Biopharma Year-End 2022 Conference Presentation

Hansa Biopharma's year-end 2022 conference presentation reports total revenue of SEK 155m and Idefirix product launch progress across Europe with market access secured in 11 countries. The company highlights positive clinical trial data in antibody-mediated rejection and advances in its imlifidase pipeline across multiple indications including anti-GBM, GBS, and DMD-related studies. With $40 million raised in a direct share issue, Hansa extended its cash runway into 2025 and progressed toward planned BLA submission in 2024.